DHTKD1 and neoplasm: The tumor growth was found to be similar and steady for all groups at the beginning, but after ~14 days the suppression of tumor growth was found to be strong and significantly superior in the Ad-E1A-treated groups, with the tumor inhibition rate of 30% in HRT-18 tumor xenografts compared to the buffer-control group (P<0.01) and 35% in HT-29 tumor xenografts compared to the buffer-control group (P<0.01).